Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4 degrees C and Room Temperature (23 degrees C)

被引:0
作者
Walker, Scott E. [1 ,2 ,3 ]
Milliken, Debbie [4 ]
Law, Shirley [5 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Dept Pharm, Res & Qual Control, Toronto, ON, Canada
[2] Sunnybrook Hlth Sci Ctr, Div Clin Pharmacol, Toronto, ON, Canada
[3] Univ Toronto, Fac Pharm, Toronto, ON, Canada
[4] Canc Care Ontario, Prov Drug Reimbursement Programs, Toronto, ON, Canada
[5] Sunnybrook Hlth Sci Ctr, Dept Pharm, Qual Control, Toronto, ON, Canada
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The bortezomib product monograph indicates that after reconstitution, the drug may be stored for up to 3 h in a syringe, and the total storage time for the reconstituted material must not exceed 8 h when exposed to normal indoor lighting. Given the product packaging and vial size, as well as the currently recommended dosage regimen (which, for a clinic treating between 1 and 10 patients daily, entails using about half a vial each day), there is potential for substantial wastage, about $13,000 for a 5-cycle course of bortezomib therapy for a single patient. The aim of this study was to evaluate the stability of bortezomib (3.5-mg vials) reconstituted with 3.5 mL of 0.9% sodium chloride (NS) to produce a 1 mg/mL solution. Methods: On study day 0, six 3.5-mg vials of bortezomib were reconstituted with 3.5 mL NS per vial, to prepare solutions of 1.0 mg/mL. Three of the vials were stored in the refrigerator, and 3 were stored at room temperature. Concentration was measured and physical inspection was completed for each vial on study days 0, 1, 4, 8, 11, 15, 18, 21, 28, 34, and 42. The intervals between study days were consistent with the recommended dosage regimen, as published in the product monograph. Bortezomib concentrations were determined by a validated, stability-indicating, liquid chromatographic method. Results: All solutions remained clear and colourless. During the study period, all solutions retained more than 98% of the initial concentration, and the amount remaining on day 42 was greater than 98% (with 95% confidence). During the study period, the absolute deviation from the known concentration for standards and quality control samples averaged less than 4%, and analytical reproducibility within a day (by coefficient of variation) was high, with error on replicate analysis averaging less than 2%. Conclusions: Bortezomib, supplied in 3.5-mg vials and reconstituted with 3.5 mL NS, is physically and chemically stable for up to 42 days at 4 degrees C or at room temperature.
引用
收藏
页码:14 / 20
页数:7
相关论文
共 8 条
  • [1] Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial
    André, P
    Cisternino, S
    Chiadmi, F
    Toledano, A
    Schlatter, J
    Fain, O
    Fontan, JE
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (09) : 1462 - 1466
  • [2] IMPORTANCE OF BETA, TYPE-II ERROR AND SAMPLE-SIZE IN DESIGN AND INTERPRETATION OF RANDOMIZED CONTROL TRIAL - SURVEY OF 71 NEGATIVE TRIALS
    FREIMAN, JA
    CHALMERS, TC
    SMITH, H
    KUEBLER, RR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1978, 299 (13) : 690 - 694
  • [3] ANALYTICAL METHODS VALIDATION - BIOAVAILABILITY, BIOEQUIVALENCE, AND PHARMACOKINETIC STUDIES
    SHAH, VP
    MIDHA, KK
    DIGHE, S
    MCGILVERAY, IJ
    SKELLY, JP
    YACOBI, A
    LAYLOFF, T
    VISWANATHAN, CT
    COOK, CE
    MCDOWALL, RD
    PITTMAN, KA
    SPECTOR, S
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (03) : 309 - 312
  • [4] SAMPLE-SIZE CALCULATIONS FOR CLINICAL-PHARMACOLOGY STUDIES
    STOLLEY, PD
    STROM, BL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (05) : 489 - 490
  • [5] AVOIDING COMMON FLAWS IN STABILITY AND COMPATIBILITY STUDIES OF INJECTABLE DRUGS
    TRISSEL, LA
    [J]. AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1983, 40 (07): : 1159 - 1160
  • [6] STABILITY STUDIES - 5 YEARS LATER
    TRISSEL, LA
    FLORA, KP
    [J]. AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1988, 45 (07): : 1569 - 1571
  • [7] Walker Scott E., 1994, Canadian Journal of Hospital Pharmacy, V47, P15
  • [8] 1990, CAN J HOSP PHARM, V43, P3